

#### 4.0.03 DOC Cmte minutes

### Neonatal Infection Guideline Update- Committee Meeting

**Date:** 06 March 2020

**Location:** NICE Office London

**Minutes:** Final

<b>Committee members present:</b>	
Waqar Shah (WS) (Chair)	Day 1 Present for notes 1 – 7
Sumiah Al-Azeib (SA)	Day 1 Present for notes 1 – 7
Philip Banfield (PB)	Day 1 Present for notes 1 – 7
Melanie Carpenter (MC)	Day 1 Present for notes 1 – 7
Mark Davies (MD)	Day 1 Present for notes 1 – 7
Nicole Gannon (NG)	Day 1 Present for notes 1 – 7
Jim Gray (JG)	Day 1 Present for notes 1 – 7
Paul Heath (PH)	Day 1 Present for notes 1 – 7
Stephanie Jenkins (SJ)	Day 1 Present for notes 1 – 7
Jane Plumb (JP)	Day 1 Present for notes 1 – 7
Aung Soe (AS)	Day 1 Present for notes 1 – 7

#### 4.0.03 DOC Cmte minutes

<b>In attendance:</b>		
Clare Dadswell	NICE - Technical Analyst	Day 1 Present for notes 1 – 7
Chris Harris	NICE - Project Manager	Day 1 Present for notes 1 – 7
Kathryn Hopkins	NICE - Technical Adviser	Day 1 Present for notes 1 – 7
Justine Karpusheff	NICE - Guideline Commissioning Manager	Day 1 Present for notes 1 – 2
Gabriel Rogers	NICE - Technical Adviser Health Economics	Day 1 Present for notes 1 – 7
Stacey Chang-Douglass	NICE-Technical Analyst Health Economics	Day 1 Present for notes 1 – 7
Sue Spiers	NICE - Associate Director	Day 1 Present for notes 1 – 4

<b>Apologies:</b>	
Richard Tubman	Consultant Neonatologist

<b>Observer:</b>	
Brett Doble	Technical Adviser (Health Economics)
Jeremy Dietz	Technical Analyst (Health Economics)

Friday 6 March 2020

<b>1. Welcome and objectives for the meeting</b>
<p>The Chair welcomed the Committee members and attendees to the 6<sup>th</sup> meeting on Neonatal infections.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the objectives of the meeting, which included:</p> <ul style="list-style-type: none"><li>• Discussing evidence on the clinical and cost effectiveness of intrapartum antibiotic prophylaxis for preventing early-onset neonatal infection</li><li>• A presentation and update on Health Economic models</li><li>• An update on the optimal antibiotic treatment regimen and the clinical and</li></ul>

#### 4.0.03 DOC Cmte minutes

cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was: prevention and treatment of neonatal infection.

The DOI register was reviewed by the Chair and Committee and the Chair asked everyone to verbally declare any interests that have arisen since the last meeting. These are noted below.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Jane Plumb	lay member	Direct non-financial professional and personal	Appointed to the role of trustee for the Confederation of Meningitis Organisations (an international charity).	Declare and participate
Philip Barnfield	Obstetrician	Direct financial	Carry out medicolegal work, through preparing medicolegal reports, and appearing as an expert witness related to one case of GBS screening in 2014	Declare and participate Not specific to any topic covered in the scope of the guideline.

The DOIs were considered by the Chair, no conflict of interest was identified for the meeting, and all Committee members were eligible to attend the Committee meeting and contribute to the discussions.

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meetings which took place on the 16<sup>th</sup> and 17<sup>th</sup> January 2020.

#### **2 & 3. RQ2.1 What is the clinical and cost effectiveness of intrapartum antibiotic prophylaxis for preventing early-onset neonatal infection?**

- **Presentation of clinical evidence**
- **Discussion**

#### 4.0.03 DOC Cmte minutes

The Chair introduced CD, Technical Analyst, who gave a presentation on the clinical evidence of intrapartum antibiotic prophylaxis for preventing early-onset neonatal infection. The Committee discussed and commented on the evidence. The Chair thanked CD for their presentation.

**4. RQ3.1 What is the clinical and cost effectiveness of immediate delivery versus expectant management in women between 34- and 37- weeks gestation with preterm prelabour prolonged rupture of membranes and vaginal or urine group B streptococcus detection?**

- **Presentation on Health Economics**

The Chair introduced SC, Technical Analyst, who gave a presentation and update on the health economic models. The Committee discussed the health economic models presented. The Chair thanked SC for her presentation.

**5. RQ6.1 What investigations should be performed before starting treatment in babies with symptoms of late-onset neonatal infection?**

- **Update and discussion**

The Chair in discussion with the Committee agreed to carry this item forward to the next meeting.

**6. RQ7.1 What is the optimal antibiotic treatment regimen for suspected late-onset neonatal infection?**

**RQ7.2 What is the clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection?**

- **Update**

The Chair introduced CD, Technical Adviser, who presented an update on clinical evidence. The Chair facilitated a Committee discussion and thanked the Committee for their comments. The Chair thanked CD for the update presentation.

**7. AOB, summary and next steps**

The Chair thanked the Committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

**Date of next meeting:** Monday 13<sup>th</sup> July 2020

**Location of next meeting:** Virtual committee meeting by Zoom